First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy
Objective. Comparison of the cardioprotective efficacy of valsartan/sacubitril and candesartan in women with heart failure (HF) and an initially reduced left ventricular ejection fraction receiving breast cancer chemotherapy.Material and methods. A prospective study included 112 women aged 53 to 65...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-10-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/3746 |
| _version_ | 1827961882685734912 |
|---|---|
| author | S. G. Kanorskiy V. P. Pavlovets |
| author_facet | S. G. Kanorskiy V. P. Pavlovets |
| author_sort | S. G. Kanorskiy |
| collection | DOAJ |
| description | Objective. Comparison of the cardioprotective efficacy of valsartan/sacubitril and candesartan in women with heart failure (HF) and an initially reduced left ventricular ejection fraction receiving breast cancer chemotherapy.Material and methods. A prospective study included 112 women aged 53 to 65 years with systolic heart failure, who received surgical treatment for breast cancer followed by adjuvant polychemotherapy according to the FAC scheme (fluorouracil + doxorubicin + cyclophosphamide) - 6 cycles with intervals between 21 days of administration. After randomization, HF therapy with nebivolol, eplerenone, and valsartan/sacubitril (n = 55) or candesartan (n = 57) was performed. A general clinical laboratory study, electrocardiography, daily Holter monitoring of an electrocardiogram, echocardiography, a 6-minute walk test, quality of life assessment were performed initially and repeatedly after 1, 3, and 6 chemotherapy courses.Results. Both groups showed a tendency to troponin I level increase and a significant decrease in the concentration of N-terminal prohormone of brain natriuretic peptide. Only the valsartan/sacubitril group showed a statistically significant increase in the 6-minute walk distance, suppression of ventricular cardiac arrhythmias, improved indicators of systolic function of the left ventricle and quality of life when the Minnesota questionnaire was used.Conclusion. The first randomized trial of valsartan/sacubitril showed superiority compared to candesartan in the treatment of heart failure in women with breast cancer, who received adjuvant chemotherapy, which included anthracycline antibiotic, doxorubicin. |
| first_indexed | 2024-04-09T16:33:52Z |
| format | Article |
| id | doaj.art-eb3aa7b2070c420d914421cf81fd0851 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:33:52Z |
| publishDate | 2019-10-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-eb3aa7b2070c420d914421cf81fd08512023-04-23T06:56:59ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-10-01016424810.21518/2079-701X-2019-16-42-483328First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapyS. G. Kanorskiy0V. P. Pavlovets1Kuban State Medical UniversityMAMMAE Multidisciplinary ClinicObjective. Comparison of the cardioprotective efficacy of valsartan/sacubitril and candesartan in women with heart failure (HF) and an initially reduced left ventricular ejection fraction receiving breast cancer chemotherapy.Material and methods. A prospective study included 112 women aged 53 to 65 years with systolic heart failure, who received surgical treatment for breast cancer followed by adjuvant polychemotherapy according to the FAC scheme (fluorouracil + doxorubicin + cyclophosphamide) - 6 cycles with intervals between 21 days of administration. After randomization, HF therapy with nebivolol, eplerenone, and valsartan/sacubitril (n = 55) or candesartan (n = 57) was performed. A general clinical laboratory study, electrocardiography, daily Holter monitoring of an electrocardiogram, echocardiography, a 6-minute walk test, quality of life assessment were performed initially and repeatedly after 1, 3, and 6 chemotherapy courses.Results. Both groups showed a tendency to troponin I level increase and a significant decrease in the concentration of N-terminal prohormone of brain natriuretic peptide. Only the valsartan/sacubitril group showed a statistically significant increase in the 6-minute walk distance, suppression of ventricular cardiac arrhythmias, improved indicators of systolic function of the left ventricle and quality of life when the Minnesota questionnaire was used.Conclusion. The first randomized trial of valsartan/sacubitril showed superiority compared to candesartan in the treatment of heart failure in women with breast cancer, who received adjuvant chemotherapy, which included anthracycline antibiotic, doxorubicin.https://www.med-sovet.pro/jour/article/view/3746breast cancerheart failurevalsartan/sacubitrilcandesartandoxorubicin |
| spellingShingle | S. G. Kanorskiy V. P. Pavlovets First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy Медицинский совет breast cancer heart failure valsartan/sacubitril candesartan doxorubicin |
| title | First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy |
| title_full | First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy |
| title_fullStr | First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy |
| title_full_unstemmed | First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy |
| title_short | First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy |
| title_sort | first experience of using valsartan sacubitril in women with heart failure and breast cancer receiving anthracycline based adjuvant chemotherapy |
| topic | breast cancer heart failure valsartan/sacubitril candesartan doxorubicin |
| url | https://www.med-sovet.pro/jour/article/view/3746 |
| work_keys_str_mv | AT sgkanorskiy firstexperienceofusingvalsartansacubitrilinwomenwithheartfailureandbreastcancerreceivinganthracyclinebasedadjuvantchemotherapy AT vppavlovets firstexperienceofusingvalsartansacubitrilinwomenwithheartfailureandbreastcancerreceivinganthracyclinebasedadjuvantchemotherapy |